Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2009-07-16
2011-10-11
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S317000, C530S326000
Reexamination Certificate
active
08034782
ABSTRACT:
The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.
REFERENCES:
patent: 5489670 (1996-02-01), Currie et al.
patent: 5518888 (1996-05-01), Waldman
patent: 5578709 (1996-11-01), Woiszwillo
patent: 5601990 (1997-02-01), Waldman
patent: 5731159 (1998-03-01), Waldman
patent: 5879656 (1999-03-01), Waldman
patent: 5928873 (1999-07-01), Waldman
patent: 5969097 (1999-10-01), Wiegand et al.
patent: 6060037 (2000-05-01), Waldman
patent: 6235782 (2001-05-01), Pamukcu et al.
patent: 7041786 (2006-05-01), Shailubhai et al.
patent: 2002/0078683 (2002-06-01), Katayama et al.
patent: 2002/0128176 (2002-09-01), Forssmann et al.
patent: 2003/0073628 (2003-04-01), Shailubhai et al.
patent: 2005/0016244 (2005-01-01), Hergemoller
patent: 2005/0032684 (2005-02-01), Cetin et al.
patent: 2006/0086653 (2006-04-01), St. Germain
patent: 2007/0101158 (2007-05-01), Elliott
patent: 2008/0137318 (2008-06-01), Rangaraj et al.
patent: 2008/0151257 (2008-06-01), Yasuda et al.
patent: WO-0125266 (2001-04-01), None
patent: WO-02062369 (2002-08-01), None
patent: WO-02078683 (2002-10-01), None
patent: WO-02098912 (2002-12-01), None
patent: WO-2005016244 (2005-02-01), None
patent: WO-2006086653 (2006-08-01), None
patent: WO-2007022531 (2007-02-01), None
patent: WO-2007101158 (2007-09-01), None
patent: WO-2008137318 (2008-11-01), None
patent: WO-2008151257 (2008-12-01), None
patent: WO-2009149278 (2009-12-01), None
patent: WO-2009149279 (2009-12-01), None
Hess et. al. GCAP-II: isolation and characterization of the circulating form of human uroguanylin, Federation of European Biochemical Societies Letters: (374) 34-38, 1995.
Askling et al. “Colorectal Cancer Rates Among First Degree Relatives of Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study”,Lancet, 357:262-266 (2001).
Barbara et al., “A role for inflammation in irritable bowel syndrome”,Gut., 51(Suppl. 1):141-144 (2002).
Basoglu et al., In: Proceeding of the Second FEPS Congress, Jun. 29-Jul. 4, 1999, Prague, Czech Republic, If2.cuni.cz/physiolres/feps/basoglu.htm.
Baxter et al., “Natriuretic peptides and myocardial ischaemia”,Basic Res. Cardiol., 99(2):71-75 (2004).
Bergers et al., “Extrinsic regulators of epithelial tumor progression: metalloproteinases”,Curr. Opin. Gen. Dev., 10:120-127 (2000).
Bhakdi et al., “Release of interleukin-1 beta associated with potent cytocidal action of staphylococcal alpha-toxin on human monocytes”,Infect. Immun., 57(11):3512-3519 (1989).
Brown et al., “A Receptor-Medicated Pathway for Cholesterol Homeostasis” ,Sci., 232:34-47 (1986).
Burnham, N.L., “Polymers for delivering peptides and proteins”,Am. J. Hosp. Pharm., 51:210-218 (1994).
Caliceti et al., “Synthesis and biopharmaceutical characterisation of new poly (hydroxyethylaspartamide) copolymers as drug carriers”,Biochimica et Biophysica Acta, 1528:177-186 (2001).
Camilleri et al., “Management of the irritable bowel syndrome”,Gastroenterol., 120:652-668 (2001).
Carrithers et al., “Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues”,Proc. Natl. Acad. Sci. USA, 93:14827-14832 (1996).
Cermak et al., “Natriuretic peptides increase a K+ conductance in rat mesangial cells”,Pflügers Arch.-Eur. J. Physiol., 431:571-577 (1996).
Cheng et al., “Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis”,Cell, 63:827-834 (1990).
Chino et al., “Topological isomers of human uroguanylin: interconversion between biologically active and inactive isomers”,FEBS Letters, 421:27-31 (1998).
Cohen et al., “Guanylin mRNA expression in human intestine and colorectal adenocarcinoma”,Lab. Invest., 78:101-108 (1998).
Collins, SM., “The Relationship of Enteric Microbial Infection and Functional Bowel Disorders”,J. Clin. Gastroenterol, 41 Suppl. 1:S30-32 (2007).
Cui et al., “The Permissive Effect of Zinc Deficiency on Uroguanylin and Inducible Nitric Oxide Synthase Gene Upregulation in Rat Intestine Induced by Interleukin 1a is Rapidly Reversed by Zinc Repletion”,J. Nutri., 133(1):51-56 (2003).
Currie et al., “Guanylin: an endogenous activator of intestinal guanylate cyclase”,Proc. Natl. Acad. Sci. USA, 89:947-951 (1992).
Database BIOSIS (Online), Biosciences Information Service, Philadelphia, PA, U.S., Apr. 2006, Refaat et al., “Sp304, an analog of uroguanylin, ameliorates inflammation in a model of experimental colitis”, XP002540570, Database Accession No. PREV200600503788.
De Luca et al., “Inflammation and Insulin Resistance”, FEBS Letter, 582:97-105 (2008).
De Sauvage et al., “Precursor structure, expression, and tissue distribution of human guanylin”,Proc. Natl. Acad. Sci. USA, 89:9089-9093 (1992).
Delvaux et al., “Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome”,Aliment Pharmacol. Ther., 12:849-855 (1998).
Dennis et al. “Off by a whisker”,Nature, 442:739-741 (2006).
Deschner et al., “Proliferative defects in ulcerative colitis patients”,Can Invest., 1:41-47 (1983).
Dunfield et al., “Energy parameters in polypeptides. 8. Empirical potential energy algorithm for the conformational analysis of large molecules”,J. Phys. Chem., 82:2609-2616 (1978).
Eastwood, G. “Epithelial Renewal in Premalignant Conditions of the Gastrointestinal Tract: A Review”,J. Clin. Gastroenterol., 14(1):S29-S33 (1992).
Ettorre et al., “Mucosal changes in ileal pouches after restorative proctocolectomy for ulcerative and Crohn's colitis”, Dis. Colon Rectum, 43:1743-1748 (2000).
Evan et al., “Proliferation, cell cycle and apoptosis in cancer”,Nature(London), 411:342-348 (2001).
Forte, L.R., “Guanylin regulatory peptides: Structures, biological activites mediated by cyclic GMP and pathobiology”,Reg. Pep., 81(1-3):25-39 (1999).
Garcia et al., “Processing and characterization of human proguanylin expressed inEscherichia coli”, J. Biol. Chem., 268(30):22397-22401 (1993).
Greenberg et al., “Comparison of effects of uroguanylin, guanylin, andEscherichia coliheat-stable enterotoxin STa in mouse intestine and kidney: evidence that uroguanylin is an intestinal natriuretic hormone”,J. Invest. Med., 45(5):276-282 (1997).
Guba et al., “Guanylin strongly stimulates rat duodenal HCO3- secretion: proposed mechanism and comparison with other secretagogues”,Gastroenterol., 111(6):1558-1568 (1996).
Gülcan et al., “Increased Frequency of Pre-diabetes in Patients With Irritable Bowel Syndrome”,Am. J. Med. Sci., 338:116-119 (2009).
Gülcan et al., “The Predictive Value of CPR Levels on Future Severe Renal Disease in Overweight and Obese Subjects Without Diabetes Mellitus and Hypertension”,Am. J. Med. Sci., 334:444-451 (2007).
Gura, T., “Systems for identifying new drugs are often faulty”,Sci., 278:1041-1042 (1997).
Hamman et al., “ Oral delivery of peptide drugs”, BIODRUGS, 19(3):165-177 (2005).
Hamra et al., “Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal quanylate cyclase”,Proc. Natl. Acad. Sci. USA, 90:10464-10468 (1993).
Harris et al., “Drug evaluation: lina
Elrifi Ivor R.
Gupta Anish
Kozakiewicz Cynthia A.
Lieb Jeanette
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Agonists of guanylate cyclase useful for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agonists of guanylate cyclase useful for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agonists of guanylate cyclase useful for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4289625